Predictive biomarkers for immunotherapy response in extensive-stage SCLC

ConclusionThe exploration of biomarkers for immunotherapy of SCLC is still very difficult, and it is clear that conventional  predictive biomarkers are not suitable for SCLC. At present, the molecular subtypes defined from transcription factors may have some guiding significance, which still needs to be confirmed by prospective clinical studies. In addition, the ctDNA positivity rate of SCLC is higher than that of othe r tumor types, which can also solve the dilemma of the difficulty of obtaining specimens of SCLC tissues. And the dynamic change of ctDNA also has great potential to predict the curative effect of SCLC, which is worth further clinical exploration.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research